Prospects of using olokizumab in the treatment of polymyalgia rheumatica: preliminary analysis data
BACKGROUND. Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are diseases that develop in people over 50 years of age and often require long—term glucocorticoid (GC) therapy, which is associated with a high risk of side effects. In this regard, it is emergent to search for effective steroid-sparing drugs. Interleukin-6 (IL-6) inhibitors, such as tocilizumab and sarilumab, have already proven efficiency in the treatment of PMR and GCA. However, the availability of these drugs in Russia is limited, what makes the use of a domestic IL-6 inhibitor, olokizumab, promising.
Authors
- Pavel Novikov (ORCID: https://orcid.org/0000-0003-0148-5655)
- А. Д. Мешков (ORCID: https://orcid.org/0000-0002-5187-0108)
- А. В. Торгашина (ORCID: https://orcid.org/0000-0001-8099-2107)
- А. L. Maslyanskiy (ORCID: https://orcid.org/0000-0003-2427-4148)
- Ilya Smitienko (ORCID: https://orcid.org/0000-0002-1508-3975)
- А. L. Chudinov (ORCID: https://orcid.org/0000-0002-7675-5683)
- А. В. Наумов (ORCID: https://orcid.org/0000-0002-6253-621X)
- Е. П. Иливанова (ORCID: https://orcid.org/0000-0002-9312-3768)
- E. G. Zotkin (ORCID: https://orcid.org/0000-0002-4579-2836)
- О. Н. Ткачева (ORCID: https://orcid.org/0000-0002-4193-688X)
Institutions
- Sechenov University (RU)
- Pirogov Russian National Research Medical University (RU)
- Ministry of Health of the Russian Federation (RU)
Publication Details
- Journal
- Russian Journal of Geriatric Medicine
- Published
- 2025-05-05
- DOI
- https://doi.org/10.37586/2686-8636-2-2025-265-267
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00